Document is current
Any future updates will be listed below
-
Authors
Kosnopfel, Corinna http://orcid.org/0000-0002-0910-838X
Wendlinger, Simone
Niessner, Heike
Siewert, Johannes
Sinnberg, Tobias
Hofmann, Angelika
Wohlfarth, Jonas
Schrama, David
Berthold, Marion
Siedel, Claudia
Sauer, Birgit
Jayanthan, Aarthi
Lenz, Georg
Dunn, Sandra E.
Schilling, Bastian
Schittek, Birgit
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (Mildred Scheel Early Career Center Wuerzburg)
Medizinischen Fakultät, Eberhard Karls Universität Tübingen (2505-0-0)
Hiege-Stiftung gegen Hautkrebs
Deutsche Forschungsgemeinschaft (SCHI 510/12–1, Germany's Excellence Strategy—EXC2180–390900677)
Westfälische Wilhelms-Universität Münster (Open Access Publication Fund)
Universitätsklinikum Münster
- License Information
-
More Information
Article History
Received: 4 May 2023
Accepted: 10 July 2023
First Online: 19 July 2023
Declarations
:
: The use of human tissue for the generation of patient-derived melanoma short-term cultures and the isolation of melanocytes was approved by the respective local medical ethical committees (Tübingen: 43/2008B01, 16/2009B02, 40/2009B02; Würzburg: 241/2014) and experiments were performed according to the Declaration of Helsinki Principles.All animal experiments were approved by the responsible regional authority (Regierungspräsidium Tübingen, AZ HT1/18) and conducted in accordance with the institutional guidelines.
: All authors have read and approved the publication of the manuscript.
: S.E.D. and A.J. hold equity ownership of the RSK inhibitor PMD-026 (Phoenix Molecular Designs). All other authors declare that they have no competing interests.
